Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 173.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (44.0%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -0.6% (LTM)
  • Share price is 201.6% higher than minimum and 2.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (35.1x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $1 507.2 mln (-0.200% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (+1.2%)936.8
year average price 788.32  


year start price 797.45 2024-11-07

max close price 929.72 2025-03-03

min close price 625.65 2025-08-08

current price 925.81 2025-11-06
Common stocks: 900 605 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.6%
EV / LTM EBITDA: 35.1x
EV / EBITDA annualized: 27.6x
Last revenue growth (y/y):  +53.9%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +28.1%
Historical growth of EBITDA:  +59.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 843 687
Net Debt ($m): 32 651
EV (Enterprise Value): 876 338
EBITDA LTM ($m): 24 974
EV / LTM EBITDA: 35.1x
Price to Book: 58.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-06reuters.com

Lilly's experimental drug shows promise with 20.1% weight loss in mid-stage trial

2025-11-06cnbc.com

Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study

2025-11-06prnewswire.com

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

2025-11-05zacks.com

Here's Why Eli Lilly (LLY) is a Strong Momentum Stock

2025-11-05prnewswire.com

XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development

2025-11-04zacks.com

Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term

2025-11-02cnbc.com

Where the blockbuster weight loss drug market stands today — and what's coming next

2025-10-31fastcompany.com

Eli Lilly's obesity and diabetes treatments fuel growth and spark bidding war

2025-10-30seekingalpha.com

Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript

2025-10-30zacks.com

Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data